List of Tables
Summary Table: Global Market for the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, Through 2028
Table 1: Global Population, Aged 60+, 2010-2050
Table 2: Factors Leading to the Increasing Incidence of Myasthenia Gravis Worldwide
Table 3: Global Serological Testing for Myasthenia Gravis, by Type
Table 4: Targeted Drug Therapies for the Treatment of Myasthenia Gravis
Table 5: Diagnostic Challenges in the Treatment of Myasthenia Gravis
Table 6: Risks of Emerging Therapies for Myasthenia Gravis, by Type
Table 7: Global Market for the Treatment of Myasthenia Gravis, by Region, Through 2028
Table 8: North American Market for the Treatment of Myasthenia Gravis, by Country, Through 2028
Table 9: European Market for the Treatment of Myasthenia Gravis, by Country, Through 2028
Table 10: Asia-Pacific Market for the Treatment of Myasthenia Gravis, by Country, Through 2028
Table 11: Global Prevalence of Myasthenia Gravis, by Type
Table 12: Global Market for the Treatment of Generalized Myasthenia Gravis, by Region, Through 2028
Table 13: Global Market for the Treatment of Ocular Myasthenia Gravis, by Region, Through 2028
Table 14: Global Market for the Treatment of Transient Neonatal Myasthenia Gravis, by Region, Through 2028
Table 15: Global Market for Medications for the Treatment of Myasthenia Gravis, by Region, Through 2028
Table 16: Global Market for Surgical Treatment of Myasthenia Gravis, by Region, Through 2028
Table 17: Global Market for Intravenous Therapy for the Treatment of Myasthenia Gravis, by Region, Through 2028
Table 18: Global Market for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 19: Global Market for Monoclonal Antibodies for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 20: Global Market for Cholinesterase Inhibitors for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 21: Global Market for Intravenous Immunoglobulins for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 22: Global Market for Immunosuppressants for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 23: Global Market for Corticosteroids for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 24: ESG Framework for the Global Pharmaceutical Industry
Table 25: Social Framework of the Global Pharmaceutical Industry
Table 26: Top Pharma Companies: ESG Ratings
Table 27: AstraZeneca’s Contribution to Sustainable Development Goals
Table 28: AstraZeneca’s Material Focus Areas
Table 29: New Technologies for Myasthenia Gravis Treatments
Table 30: New Pharmaceuticals for the Treatment of Myasthenia Gravis
Table 31: Global Company Market Shares of Myasthenia Gravis Treatments, 2022
Table 32: Global Product Shares of Myasthenia Gravis Treatments, by Brand, 2022
Table 33: Global Sales of Myasthenia Gravis Treatments, by Brand, 2022
Table 34: Key Financials of Pharma Companies Offering Myasthenia Gravis Treatment Products, 2022
Table 35: Patents on Myasthenia Gravis Treatments, 2018-Present
Table 36: Selected Manufacturer Patents on Myasthenia Gravis Drugs, 2018-Present
Table 37: Patents on Eculizumab, 2018-Present
Table 38: Selected Manufacturer Patents on Eculizumab, 2018-Present
Table 39: Patents on Efgartigimod alfa, 2018-Present
Table 40: Selected Manufacturer Patents on Efgartigimod alfa, 2018-Present
Table 41: Patents on Rituximab, 2018-Present
Table 42: Selected Manufacturer Patents on Rituximab, 2018-Present
Table 43: Patents on Pyridostigmine, 2018-Present
Table 44: Selected Manufacturer Patents on Pyridostigmine, 2018-Present
Table 45: Patents on Privigen, 2018-Present
Table 46: Selected Manufacturer Patents on Privigen, 2018-Present
Table 47: Clinical Trials on Myasthenia Gravis, as of 2023
Table 48: Mergers and Acquisitions, 2019-2021
Table 49: AbbVie: Product Information
Table 50: AbbVie: Financial Overview, 2020-2022
Table 51: AbbVie: Key Developments, 2021-2023
Table 52: Amgen: Revenue, 2020-2022
Table 53: Amgen: Key Developments, 2021 and 2022
Table 54: Astellas Pharma: Revenue, 2020-2022
Table 55: Astellas Pharma: Key Developments, 2018-2022
Table 56: AstraZeneca: Product Information
Table 57: AstraZeneca: Revenue, 2020-2022
Table 58: AstraZeneca: Key Developments, 2022 and 2023
Table 59: Bausch Health: Product Information
Table 60: Bausch Health: Revenue, 2020-2022
Table 61: Bayer AG: Product Information
Table 62: Bayer AG: Financial Overview, 2020-2022
Table 63: Bayer AG: Key Developments, 2022 and 2023
Table 64: Biogen: Financial Overview, 2020-2022
Table 65: Biogen: Key Developments, 2018-2023
Table 66: Bristol-Myers Squibb: Product Information
Table 67: Bristol-Myers Squibb: Financial Overview, 2020-2022
Table 68: Bristol-Myers Squibb: Key Developments, 2021-2023
Table 69: CSL: Product Information
Table 70: CSL: Revenue, 2020-2022
Table 71: CSL: Recent Developments, 2022
Table 72: Daiichi Sankyo: Product Information
Table 73: Daiichi Sankyo: Financial Overview, 2020-2022
Table 74: Daiichi Sankyo: Key Developments, 2022 and 2023
Table 75: Roche: Product Information
Table 76: Roche: Revenue, 2020-2022
Table 77: Roche: Key Developments, 2021-2023
Table 78: Gilead Sciences: Financial Overview, 2020-2022
Table 79: Gilead Sciences: Key Developments, 2022
Table 80: GlaxoSmithKline plc: Product Segments
Table 81: GlaxoSmithKline plc: Financial Overview, 2020-2022
Table 82: GlaxoSmithKline plc: Recent Developments, 2022
Table 83: Merck & Co. Inc.: Business Segments
Table 84: Merck & Co. Inc.: Financial Overview, 2020-2022
Table 85: Merck & Co. Inc.: Key Developments, 2022
Table 86: Novartis: Product Information
Table 87: Novartis: Financial Overview, 2020-2022
Table 88: Novartis: Key Developments, 2023
Table 89: Pfizer Inc: Product Segments
Table 90: Pfizer Inc: Financial Overview, 2020-2022
Table 91: Pfizer Inc: Top Brands, 2022
Table 92: Pfizer Inc: Key Developments, 2019-2023
Table 93: Sanofi: Business Segments
Table 94: Sanofi: Annual Revenue, 2020-2022
Table 95: Sanofi: Key Developments, 2021-2023
Table 96: Servier: Annual Revenue, 2020-2022
Table 97: Servier: Key Developments, 2022 and 2023
Table 98: Teva: Financial Overview, 2020-2022
Table 99: Teva: Key Developments, 2021-2023
Table 100: Acronyms
List of Figures
Summary Figure A: Global Market for the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, 2020-2028
Summary Figure B: Global Market Shares of the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, 2022
Figure 1: Global Factors Leading to the Prevalence of Myasthenia Gravis, by Region, 2022
Figure 2: Global Market Shares of Myasthenia Gravis Treatments, by Region, 2022
Figure 3: North American Market Shares of Myasthenia Gravis Treatments, by Country, 2022
Figure 4: European Market Shares of Myasthenia Gravis Treatments, by Country, 2022
Figure 5: Asia-Pacific Market Shares of Myasthenia Gravis Treatments, by Country, 2022
Figure 6: Global Distribution of Types of Myasthenia Gravis, 2022
Figure 7: Global Market Shares of Myasthenia Gravis Treatments, by Treatment Modality, 2022
Figure 8: Global Market Shares of Myasthenia Gravis Treatments, by Type of Product, Through 2022
Figure 9: Global Electricity Production from Renewable Sources, 2017-2021
Figure 10: Global Recycled Waste, 2017-2021
Figure 11: Global CO<sub>2</sub> Emissions, 2017-2021
Figure 12: Global Company Market Shares of Myasthenia Gravis Treatments, 2022
Figure 13: Global Sales of Myasthenia Gravis Treatments, by Brand, 2022
Figure 14: AbbVie: Revenue Shares, by Country, 2022
Figure 15: Bristol-Myers Squibb: Revenue Share, by Country/Region, 2022
Figure 16: Daiichi Sankyo: Market Share, by Country/Region, 2022
Figure 17: Gilead Sciences: Revenue, by Type of Product, 2022
Figure 18: GlaxoSmithKline plc: Annual Revenue, by Segment, 2022
Figure 19: Merck & Co. Inc.: Annual Revenue, Pharmaceutical Segment, 2022
Figure 20: Novartis Innovative Medicines: Market Share, by Country/Region, 2022
Figure 21: Novartis Sandoz: Market Share, by Country/Region 2022
Figure 22: Sanofi: Revenue, by Region, 2022
Figure 23: Sanofi: Revenue, by Segment, 2022
Figure 24: Teva: Market Share, by Region, 2022
